Drug Trial Radar · NCT07679360
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Dec 2030
Study completion Dec 2032
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast cancer with invasive residual cancer after neoadjuvant treatment, and to explore the PK characteristics and immunogenicity of SHR-A1811 and Adebrelimab.
Conditions
- Triple Negative Breast Cancer
Interventions
Trastuzumab Rezetecan for InjectionDrug
Trastuzumab Rezetecan for Injection.
Adebrelimab InjectionDrug
Adebrelimab Injection.
Capecitabine tabletsDrug
Capecitabine Tables.
Pembrolizumab injectionDrug
Pembrolizumab Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival (iDFS)Time frame: Until study completion, assessed up to approximately 5 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.